Evaluation of the hs-CRP reducing Effect of Rosuvastatin - a placebo controlled randomized multicentre phase IIIb study in hypertensive patients with an increased global risk of developing fatal cardiovascular disease - the ELECTRA study.
Study identifier:D3560L00038
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
Evaluation of the hs-CRP reducing Effect of Rosuvastatin - a placebo controlled randomized multicentre phase IIIb study in hypertensive patients with an increased global risk of developing fatal cardiovascular disease - the ELECTRA study.
Medical condition
dyslipidaemia
Phase
Phase 3
Healthy volunteers
-
Study drug
-
Sex
-
Actual Enrollment
-
Study type
Interventional
Age
-
Date
Study Start Date: 01 May 2004
Primary Completion Date: -
Study Completion Date: -
Study design
Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -
Verification:
Verified 01 Nov 2013 by AstraZeneca
Sponsors
AstraZeneca
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|
